Insider Selling: Alimera Sciences, Inc. (ALIM) CEO Sells 52,900 Shares of Stock

Alimera Sciences, Inc. (NASDAQ:ALIM) CEO C. Daniel Myers sold 52,900 shares of the firm’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total transaction of $65,067.00. Following the completion of the transaction, the chief executive officer now directly owns 154,411 shares of the company’s stock, valued at $189,925.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Alimera Sciences, Inc. (NASDAQ ALIM) remained flat at $$1.24 during trading on Thursday. 283,499 shares of the company’s stock were exchanged, compared to its average volume of 168,400. Alimera Sciences, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $1.72. The firm has a market cap of $85.74, a price-to-earnings ratio of -4.00 and a beta of 2.15. The company has a debt-to-equity ratio of -0.71, a quick ratio of 4.65 and a current ratio of 4.84.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. analysts expect that Alimera Sciences, Inc. will post -0.27 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Alimera Sciences stock. PNC Financial Services Group Inc. raised its holdings in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 180,300 shares of the biopharmaceutical company’s stock after purchasing an additional 35,200 shares during the quarter. PNC Financial Services Group Inc. owned approximately 0.28% of Alimera Sciences worth $251,000 at the end of the most recent reporting period. 41.78% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently weighed in on ALIM shares. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Alimera Sciences in a research note on Wednesday, November 22nd. Cowen reissued a “buy” rating on shares of Alimera Sciences in a research note on Thursday, November 2nd. Zacks Investment Research raised Alimera Sciences from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Finally, ValuEngine raised Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Alimera Sciences currently has an average rating of “Hold” and a consensus target price of $3.38.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Alimera Sciences, Inc. (ALIM) CEO Sells 52,900 Shares of Stock” was reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.

Leave a Reply